Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros




Base de datos
Asunto de la revista
Intervalo de año de publicación
1.
Cell Death Dis ; 14(5): 344, 2023 05 30.
Artículo en Inglés | MEDLINE | ID: mdl-37253771

RESUMEN

Cardiac hypertrophy is a common structural remodeling in many cardiovascular diseases. Recently, long non-coding RNAs (LncRNAs) were found to be involved in the physiological and pathological processes of cardiac hypertrophy. In this study, we found that LncRNA KCND1 (LncKCND1) was downregulated in both transverse aortic constriction (TAC)-induced hypertrophic mouse hearts and Angiotensin II (Ang II)-induced neonatal mouse cardiomyocytes. Further analyses showed that the knockdown of LncKCND1 impaired cardiac mitochondrial function and led to hypertrophic changes in cardiomyocytes. In contrast, overexpression of LncKCND1 inhibited Ang II-induced cardiomyocyte hypertrophic changes. Importantly, enhanced expression of LncKCND1 protected the heart from TAC-induced pathological cardiac hypertrophy and improved heart function in TAC mice. Subsequent analyses involving mass spectrometry and RNA immunoprecipitation assays showed that LncKCND1 directly binds to YBX1. Furthermore, overexpression of LncKCND1 upregulated the expression level of YBX1, while silencing LncKCND1 had the opposite effect. Furthermore, YBX1 was downregulated during cardiac hypertrophy, whereas overexpression of YBX1 inhibited Ang II-induced cardiomyocyte hypertrophy. Moreover, silencing YBX1 reversed the effect of LncKCND1 on cardiomyocyte mitochondrial function and its protective role in cardiac hypertrophy, suggesting that YBX1 is a downstream target of LncKCND1 in regulating cardiac hypertrophy. In conclusion, our study provides mechanistic insights into the functioning of LncKCND1 and supports LncKCND1 as a potential therapeutic target for pathological cardiac hypertrophy.


Asunto(s)
ARN Largo no Codificante , Factores de Transcripción , Animales , Ratones , Angiotensina II/farmacología , Cardiomegalia/metabolismo , Ratones Endogámicos C57BL , Miocitos Cardíacos/metabolismo , ARN Largo no Codificante/genética , ARN Largo no Codificante/metabolismo , Canales de Potasio Shal/metabolismo , Factores de Transcripción/metabolismo
2.
Eur J Pharmacol ; 923: 174892, 2022 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-35358494

RESUMEN

Montelukast, cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, is used clinically for patients with asthma, chronic obstructive pulmonary diseases (COPD), and allergic rhinitis. It has been reported that CysLT1R antagonists could reduce the risks of cardiovascular diseases in animal studies. Cardiac fibrosis is one of the major causes of heart failure. But little is known about the role of Montelukast in cardiac fibrosis and its underlying mechanism. In transverse aortic constriction (TAC) mice, Montelukast improved cardiac pumping function and inhibited cardiac fibrosis by down-regulation of the proteins related to the fibrosis, such as connective tissue growth factor (CTGF), Transforming Growth Factor ß (TGF-ß), and Alpha-smooth muscle actin (α-SMA). Montelukast reduced cell proliferation and collagen production in neonatal cardiac fibroblasts (CFs) with the pretreatment of 20% serum, while down-regulating the expression of TGF-ß, CTGF and α-SMA. Molecules docking methods estimated a high affinity of Montelukast to Apelin receptor (APJ) and an effective chemical structure for Montelukast binding APJ. In Chinese hamster ovary (CHO) cells with stable overexpressing APJ, Montelukast inhibited forskolin (1 µM)-mediated cyclic adenosine monophosphate (cAMP) production and extracellular signal-regulated kinase1/2 (ERK1/2) phosphorylation, while these effects were reversed by pertussis toxin (PTX) pretreatment. APJ silence disrupted the effects of Montelukast in CFs pretreatment by serum 20%. So we concluded that Montelukast inhibited cardiac fibrosis due presumably to the coupling to the APJ-mediated Gi signaling pathway, which may be a promising therapeutic target for cardiac fibrosis.


Asunto(s)
Acetatos , Animales , Células CHO , Cricetinae , Cricetulus , Ciclopropanos , Fibrosis , Humanos , Ratones , Quinolinas , Receptores de Leucotrienos , Sulfuros , Factor de Crecimiento Transformador beta
3.
IEEE Comput Graph Appl ; 37(2): 42-53, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28320644

RESUMEN

Visual clutter is a common challenge when visualizing large rank time series data. WikiTopReader, a reader of Wikipedia page rank, lets users explore connections among top-viewed pages by connecting page-rank behaviors with page-link relations. Such a combination enhances the unweighted Wikipedia page-link network and focuses attention on the page of interest. A set of user evaluations shows that the system effectively represents evolving ranking patterns and page-wise correlation.

4.
Nanoscale ; 8(27): 13342-51, 2016 Jul 21.
Artículo en Inglés | MEDLINE | ID: mdl-27341650

RESUMEN

Optical trapping and manipulation of nanoparticles (NPs) have been widely used in nanotechnology and biology. Here, we demonstrate an optically directed assembly (ODA) route for bottom-up fabrication of stable nanostructured grating patterns in solution using laser standing evanescent wave (LSEW) fields. The control mechanism is the intriguing cooperative action of the periodically line-centered attractive optical gradient force and the near field dipolar coupling force induced by LSEW, which leads to assembly of the colloidal silver NPs into robust grating patterns within minutes. The anisotropic polarization nature of the grating patterns was studied further by examining the morphology correlation of the surface-enhanced Raman scattering (SERS)-based signal amplification. We show the LSEW ODA method can optimize and stabilize the strongest dipolar coupling style among the NPs during pattern assembly. These results advance the further understanding of ODA of colloid NPs and might have many potential applications in SERS, catalysis, nanophotonics and nano-fabrication.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA